🚀 VC round data is live in beta, check it out!
Ocular Therapeutix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ocular Therapeutix and similar public comparables like Dermapharm Holding, Wockhardt, BioKangtai, Dianthus Therapeutics and more.
Ocular Therapeutix Overview
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Founded
2006
HQ
Employees
274
Website
Sectors
Financials (LTM)
EV
$2B
Ocular Therapeutix Financials
Ocular Therapeutix reported last 12-month revenue of $53M and negative EBITDA of ($274M).
In the same LTM period, Ocular Therapeutix generated $46M in gross profit, ($274M) in EBITDA losses, and had net loss of ($274M).
Revenue (LTM)
Ocular Therapeutix P&L
In the most recent fiscal year, Ocular Therapeutix reported revenue of $52M and EBITDA of ($250M).
Ocular Therapeutix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $53M | XXX | $52M | XXX | XXX | XXX |
| Gross Profit | $46M | XXX | $45M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 87% | XXX | XXX | XXX |
| EBITDA | ($274M) | XXX | ($250M) | XXX | XXX | XXX |
| EBITDA Margin | (517%) | XXX | (481%) | XXX | XXX | XXX |
| EBIT Margin | (528%) | XXX | (520%) | XXX | XXX | XXX |
| Net Profit | ($274M) | XXX | ($266M) | XXX | XXX | XXX |
| Net Margin | (518%) | XXX | (512%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ocular Therapeutix Stock Performance
Ocular Therapeutix has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Ocular Therapeutix's stock price is $11.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-1.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOcular Therapeutix Valuation Multiples
Ocular Therapeutix trades at 32.9x EV/Revenue multiple, and (6.4x) EV/EBITDA.
EV / Revenue (LTM)
Ocular Therapeutix Financial Valuation Multiples
As of March 21, 2026, Ocular Therapeutix has market cap of $2B and EV of $2B.
Equity research analysts estimate Ocular Therapeutix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ocular Therapeutix has a P/E ratio of (8.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 32.9x | XXX | 33.6x | XXX | XXX | XXX |
| EV/EBITDA | (6.4x) | XXX | (7.0x) | XXX | XXX | XXX |
| EV/EBIT | (6.2x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 37.6x | XXX | 38.4x | XXX | XXX | XXX |
| P/E | (8.8x) | XXX | (9.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ocular Therapeutix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ocular Therapeutix Margins & Growth Rates
Ocular Therapeutix's revenue in the last 12 month grew by 31%.
Ocular Therapeutix's revenue per employee in the last FY averaged $0.2M.
Ocular Therapeutix's rule of 40 is (486%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ocular Therapeutix's rule of X is (440%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ocular Therapeutix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | (517%) | XXX | (481%) | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (486%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (440%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 106% | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 127% | XXX | 216% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 382% | XXX | 379% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 607% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ocular Therapeutix Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dermapharm Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Wockhardt | XXX | XXX | XXX | XXX | XXX | XXX |
| BioKangtai | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ocular Therapeutix M&A Activity
Ocular Therapeutix acquired XXX companies to date.
Last acquisition by Ocular Therapeutix was on XXXXXXXX, XXXXX. Ocular Therapeutix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ocular Therapeutix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOcular Therapeutix Investment Activity
Ocular Therapeutix invested in XXX companies to date.
Ocular Therapeutix made its latest investment on XXXXXXXX, XXXXX. Ocular Therapeutix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ocular Therapeutix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ocular Therapeutix
| When was Ocular Therapeutix founded? | Ocular Therapeutix was founded in 2006. |
| Where is Ocular Therapeutix headquartered? | Ocular Therapeutix is headquartered in United States. |
| How many employees does Ocular Therapeutix have? | As of today, Ocular Therapeutix has over 274 employees. |
| Who is the CEO of Ocular Therapeutix? | Ocular Therapeutix's CEO is Pravin U. Dugel. |
| Is Ocular Therapeutix publicly listed? | Yes, Ocular Therapeutix is a public company listed on Nasdaq. |
| What is the stock symbol of Ocular Therapeutix? | Ocular Therapeutix trades under OCUL ticker. |
| When did Ocular Therapeutix go public? | Ocular Therapeutix went public in 2014. |
| Who are competitors of Ocular Therapeutix? | Ocular Therapeutix main competitors are Dermapharm Holding, Wockhardt, BioKangtai, Dianthus Therapeutics. |
| What is the current market cap of Ocular Therapeutix? | Ocular Therapeutix's current market cap is $2B. |
| What is the current revenue of Ocular Therapeutix? | Ocular Therapeutix's last 12 months revenue is $53M. |
| What is the current revenue growth of Ocular Therapeutix? | Ocular Therapeutix revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Ocular Therapeutix? | Current revenue multiple of Ocular Therapeutix is 32.9x. |
| Is Ocular Therapeutix profitable? | No, Ocular Therapeutix is not profitable. |
| What is the current EBITDA of Ocular Therapeutix? | Ocular Therapeutix has negative EBITDA and is not profitable. |
| What is Ocular Therapeutix's EBITDA margin? | Ocular Therapeutix's last 12 months EBITDA margin is (517%). |
| What is the current EV/EBITDA multiple of Ocular Therapeutix? | Current EBITDA multiple of Ocular Therapeutix is (6.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.